154 related articles for article (PubMed ID: 21130808)
21. Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.
Kenny PJ; Gasparini F; Markou A
J Pharmacol Exp Ther; 2003 Sep; 306(3):1068-76. PubMed ID: 12805481
[TBL] [Abstract][Full Text] [Related]
22. Role of desensitization and subunit expression for kainate receptor-mediated neurotoxicity in murine neocortical cultures.
Jensen JB; Schousboe A; Pickering DS
J Neurosci Res; 1999 Jan; 55(2):208-17. PubMed ID: 9972823
[TBL] [Abstract][Full Text] [Related]
23. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Zadow B; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
[TBL] [Abstract][Full Text] [Related]
24. Blockade of AMPA/kainate receptors can either decrease or increase the survival of cultured neocortical cells depending on the stage of maturation.
Drian MJ; Bardoul M; König N
Neurochem Int; 2001 May; 38(6):509-17. PubMed ID: 11248399
[TBL] [Abstract][Full Text] [Related]
25. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
Sevak RJ; Koek W; France CP
Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
[TBL] [Abstract][Full Text] [Related]
26. Effect of glutamate receptor antagonists on suckling-induced prolactin release in rats.
Zelena D; Makara GB; Nagy GM
Endocrine; 2003 Jul; 21(2):147-52. PubMed ID: 12897378
[TBL] [Abstract][Full Text] [Related]
27. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Hauber W; Waldenmeier MT
Eur J Pharmacol; 1994 May; 256(3):339-42. PubMed ID: 7913894
[TBL] [Abstract][Full Text] [Related]
28. Glutamatergic neurotransmission in the inferior colliculus influences intrastriatal haloperidol-induced catalepsy.
Medeiros P; Viana MB; Barbosa-Silva RC; Tonelli LC; Melo-Thomas L
Behav Brain Res; 2014 Jul; 268():8-13. PubMed ID: 24667361
[TBL] [Abstract][Full Text] [Related]
29. Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
Melo LL; Santos P; Medeiros P; Mello RO; Ferrari EA; Brandão ML; Maisonnette SS; Francisco A; Coimbra NC
Brain Res; 2010 Aug; 1349():41-7. PubMed ID: 20558148
[TBL] [Abstract][Full Text] [Related]
30. NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent.
Lanis A; Schmidt WJ
Behav Pharmacol; 2001 Apr; 12(2):143-9. PubMed ID: 11396519
[TBL] [Abstract][Full Text] [Related]
31. AMPA/kainate, NMDA, and dopamine D1 receptor function in the nucleus accumbens core: a context-limited role in the encoding and consolidation of instrumental memory.
Hernandez PJ; Andrzejewski ME; Sadeghian K; Panksepp JB; Kelley AE
Learn Mem; 2005; 12(3):285-95. PubMed ID: 15930507
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous blockade of two glutamate receptor subtypes (NMDA and AMPA) results in stressor-specific inhibition of prolactin and corticotropin release.
Zelena D; Makara GB; Jezova D
Neuroendocrinology; 1999 May; 69(5):316-23. PubMed ID: 10343172
[TBL] [Abstract][Full Text] [Related]
33. Ionotropic glutamate receptor antagonists inhibit the proliferation of granule cell precursors in the adult brain after seizures induced by pentylenetrazol.
Jiang W; Wolfe K; Xiao L; Zhang ZJ; Huang YG; Zhang X
Brain Res; 2004 Sep; 1020(1-2):154-60. PubMed ID: 15312797
[TBL] [Abstract][Full Text] [Related]
34. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain.
Kaur S; Ozer H; Starr M
Eur J Pharmacol; 1997 Aug; 332(2):153-60. PubMed ID: 9286616
[TBL] [Abstract][Full Text] [Related]
35. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.
Bubser M; Tzschentke T; Hauber W
J Neural Transm Gen Sect; 1995; 101(1-3):115-26. PubMed ID: 8695042
[TBL] [Abstract][Full Text] [Related]
36. Mechanical loading modulates glutamate receptor subunit expression in bone.
Szczesniak AM; Gilbert RW; Mukhida M; Anderson GI
Bone; 2005 Jul; 37(1):63-73. PubMed ID: 15922681
[TBL] [Abstract][Full Text] [Related]
37. Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats.
Cervo L; Samanin R
Brain Res; 1996 Aug; 731(1-2):31-8. PubMed ID: 8883851
[TBL] [Abstract][Full Text] [Related]
38. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN
Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001
[TBL] [Abstract][Full Text] [Related]
39. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization.
Tzschentke TM; Schmidt WJ
Behav Brain Res; 1997 Mar; 84(1-2):99-107. PubMed ID: 9079776
[TBL] [Abstract][Full Text] [Related]
40. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
McAllister KH
Eur J Pharmacol; 1996 Oct; 314(3):307-11. PubMed ID: 8957251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
